GENOME EDITING (LECTURE)
https://doi.org/10.57256/2949-0715-2025-4-1-84-97
Abstract
Background. Hereditary pathology has a large proportion of morbidity in modern humans. Therefore, the search for methods for treating hereditary pathology is a particularly urgent problem. Currently, there are theoretical foundations and practical solutions for the development of methods for the etiological treatment of hereditary pathology. In this regard, genome editing methods are the most promising methods for treating hereditary pathology.
The lecture discusses the historical aspects of the development of scientific thought in the field of genome editing, technological systems, protocols and stages of developing treatments for hereditary pathology using genome editing.
Conclusion. Genome editing is one of the most promising methods for treating hereditary pathology, so doctors' awareness of this issue will allow them to use the developments of molecular biology in the future to treat human genetic diseases.
About the Authors
Elena A. Tkachuk
Irkutsk State Medical University;
Scientific Center for Family Health and Human Reproduction Problems;
East Siberian Institute of Medical and Environmental Research
Russian Federation
Russian Federation
Igor Zh. Seminsky
Irkutsk State Medical University
Russian Federation
Russian Federation
References
1. Боринская С.А., Янковский Н.К. Генетика и геномика человека. популяции и этносы в пространстве и времени: эволюционные и медицинские аспекты. Вавиловский журнал генетики и селекции. 2013;17(4/2): 930-942 [Borinskaya S.A., Yankovsky N.K. Human genetics and genomics. Populations and ethnic groups in space and time: evolutionary and medical aspects. Vavilov Journal of Genetics and Breeding. 2013;17(4/2): 930-942 (In Russian)]. URL: https://vavilov.elpub.ru/jour/article/view/213/215 [дата доступа: 08.02.2025]
2. Гинтер Е.К., Пузырев В.П., Куцев С.И. Медицинская генетика: национальное руководство. Москва: ГОЭТАР-Медиа; 2022: 896 [Ginter E.K., Puzyrev V.P., Kutsev S.I. Medical genetics: national guidelines. M.: GOETAR-Media; 2022: 896 (In Russian)]. doi: 10.33029/9704-6307-9-GEN-2022-1-896
3. Ребриков Д.В. Редактирование генома человека. Вестник РГМУ. 2016;(3):4-15 [Rebrikov D.V. Human genome editing. Bulletin of RSMU. 2016;(3):4-15]. doi: 10.24075/brsmu.2016-03-01.
4. Бочков Н.П., Пузырев В.П., Смирнихина С.А Клиническая генетика: учебник. М.: ГЭОТАР-Медиа; 2022: 592 [Bochkov N.P., Puzyrev V.P., Smirnikhina S.A. Clinical genetics: textbook. Moscow:GEOTAR-Media; 2022: 592 (In Russian)]
5. Редактирование генов и геномов: Том 1. Ред. Закиян С.М., Медведев С.П., Дементьева Е.В. и др. Новосибирск: Издательство СО РАН; 2018: 369 [Gene and Genome Editing: Volume 1. Ed. Zakian S.M., Medvedev S.P., Dementyeva E.V. et al. Novosibirsk: Publishing House of the Siberian Branch of the Russian Academy of Sciences; 2018: 369 (In Russian)]
6. Perez-Pinera P., Kocak D.D., Vockley C.M. et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. doi: 10.1038/nmeth.2600.
7. Andersen J.B., Thorgeirsson S.S. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol. 2014;1(1):143-157. doi:10.2217/hep.13.4.
8. Chen R., Shi X., Yao X. et al. Specific multivalent molecules boost CRISPR-mediated transcriptional activation. Nat Commun. 2024;15(1):7222. doi:10.1038/s41467-024-51694-y.
9. Silva G., Poirot L., Galetto R. et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther. 2011;11(1):11-27. doi:10.2174/156652311794520111.
10. Bagherpoor Helabad M., Volkenandt S., Imhof P. Molecular Dynamics Simulations of a Chimeric Androgen Receptor Protein (SPARKI) Confirm the Importance of the Dimerization Domain on DNA Binding Specificity. Front Mol Biosci. 2020;7:4. doi:10.3389/fmolb.2020.00004
11. Li H., Haurigot V., Doyon Y. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011; 475(7355):217-221. doi: 10.1038/nature10177.
12. Tebas P., Stein D., Tang W.W. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-910. doi: 10.1056/NEJMoa1300662.
13. Wang S., Chen H., Tang X. et al. Molecular tools for gene manipulation in filamentous fungi. Appl Microbiol Biotechnol. 2017;101(22):8063-8075. doi:10.1007/s00253-017-8486-z.
14. Van den Ackerveken G., Marois E., Bonas U. Recognition of the bacterial avirulence protein AvrBs3 occurs inside the host plant cell. Cell. 1996;87(7):1307-1316. doi:10.1016/s0092-8674(00)81825-5.
15. Canteros B., Minsavage G., Bonas U., Pring D., Stall R. A gene from Xanthomonas campestris pv. vesicatoria that determines avirulence in tomato is related to avrBs3. Mol Plant Microbe Interact. 199;4(6):628-32. doi: 10.1094/mpmi-4-628
16. Maeder M.L., Angstman J.F., Richardson M.E. et al. Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013;31(12):1137-1142. doi:10.1038/nbt.2726
17. Koonin E.V., Makarova K.S. Origins and evolution of CRISPR-Cas systems. Philos Trans R Soc Lond B Biol Sci. 2019;374(1772):20180087. doi:10.1098/rstb.2018.0087
18. Parums D.V. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. Med Sci Monit. 2024;30:e944204. doi:10.12659/MSM.944204.
19. Yin H., Song C.Q., Dorkin J.R. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328-333. doi:10.1038/nbt.3471
20. Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43(6):1565-1575. doi:10.1046/j.1365-2958.2002.02839.x.
21. Makarova K.S., Wolf Y.I., Alkhnbashi O.S. et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015;13(11):722-36. doi: 10.1038/nrmicro3569
22. Yang P., Chou S.-J., Li J. et al. Supramolecular nanosubstrate-mediated delivery system enables CRISPR-Cas9 knockin of hemoglobin beta gene for hemoglobinopathies. Sci Adv. 2020;6(43):eabb7107. doi: 10.1126/sciadv.abb7107.
23. Alinejad T., Modarressi S., Sadri Z., Hao Z., Chen C.S. Diagnostic applications and therapeutic option of Cascade CRISPR/Cas in the modulation of miRNA in diverse cancers: promises and obstacles. J Cancer Res Clin Oncol. 2023;149(12):9557-9575. doi: 10.1007/s00432-023-04747-6.
24. Koonin E.V., Makarova K.S., Zhang F. Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67-78. doi: 10.1016/j.mib.2017.05.008.
25. Kanbar K., El Darzi R., Jaalouk D.E. Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed. Front Genet. 2024;15:1434002. doi: 10.3389/fgene.2024.1434002.
26. Savić N., Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15-21. doi: 10.1016/j.trsl.2015.09.008.
27. Chavez M., Chen X., Finn P.B., Qi L.S. Advances in CRISPR therapeutics. Nat Rev Nephrol. 2023;19(1):9-22. doi: 10.1038/s41581-022-00636-2.
28. Banda A., Impomeni O., Singh A. et al. Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies. Vaccines (Basel). 2024;12(6):636. doi: 10.3390/vaccines12060636.
29. Ветчинова А.С., Коновалова Е.В., Лунев Е.А., Иллариошкин С.Н. Технология редактирования генома и возможности ее применения в клеточной нейробиологии. Анналы клинической и экспериментальной неврологии. 2015; 9(4):59-64 [Vetchinova A.S., Konovalova E.V., Lunev E.A., Illarioshkin S.N. A genome editing technology and capabilities of its application in cellular neurobiology. Annals of Clinical and Experimental Neurology. 2015; 9(4):59-64 (In Russian)]. URL: https://cyberleninka.ru/article/n/tehnologiya-redaktirovaniya-genoma-i-vozmozhnosti-ee-primeneniya-v-kletochnoy-neyrobiologii [дата доступа: 08.02.2025]
30. Мензоров А.Г., Лукьянчикова В.А., Кораблев А.Н., Серова И.А., Фишман В.С. Практическое руководство по редактированию геномов системой CRISPR/Cas9. Вавиловский журнал генетики и селекции. 2016;20(6):930944 [Menzorov A.G., Lukyanchikova V.A., Korablev A.N., Serova I.A., Fishman V.S. Genome editing using CRISPR/Cas9 system: a practical guide. Vavilovskii Zhurnal Genetiki i Selektsii =Vavilov Journal of Genetics and Breeding. 2016;20(6):930-944 (In Russian)]. DOI 10.18699/VJ16.214
31. Orlando S.J., Santiago Y., DeKelver R.C. et al. Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. Nucleic Acids Res. 2010;38(15):e152. doi:10.1093/nar/gkq512
32. Cheng Y., Zhang N., Hussain S. et al. Integration of a FT expression cassette into CRISPR/Cas9 construct enables fast generation and easy identification of transgene-free mutants in Arabidopsis. PLoS One. 2019;14(9):e0218583. doi:10.1371/journal.pone.0218583
33. Гуревич К.Г., Сорокина Ю.А., Ураков А.Л. и др. Геннотерапевтические препараты: особенности применения в гериатрической и педиатрической практике. Обзоры по клинической фармакологии и лекарственной терапии. 2020; 18(3): 237–244 [Gurevich K.G., Sorokina Yu.A., Urakov A.L. et al. Drugs for gene therapy: features of usage in geriatrics and pediatrics. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(3):237-244 (In Russian)]. doi: 10.17816/RCF183237-244
34. Галицына Е.В., Куликова Е.А., Павельев Ю.А. и др. Современные генотерапевтические лекарственные препараты. Гены и клетки. 2024;19(1): 21–42 [Galitsyna E.V., Kulikova E.A., Paveliev Yu.A. et al. Modern gene therapy drugs. Genes & Cells. 2024;19(1): 21–42 (In Russian)]. doi: 10.17816/gc601855
35. Ткачук Е.А., Семинский И.Ж. Роль генетики в современной медицине. Байкальский медицинский журнал. 2022;1(1):81-88 [Tkachuk E.A., Seminsky I.Zh. The role of genetics in modern medicine. Baikal Medical Journal. 2022;1(1):81-88 (In Russian)]. doi: 10.57256/2949-0715-2022-1-81-88
36. Пестрикова А.А. Правовые и этические нормы редактирования генома человека. Журнал зарубежного законодательства и сравнительного правоведения. 2021;17(5):37-51 [Pestrikova A.A. Analysis of Legal and Ethical Standards in the Field of Human Gene Editing. Journal of Foreign Legislation and Comparative Law. 2021;17(5):37-51 (In Russian)]. doi: 10.12737/jflcl.2021.052
Review
For citations:
Tkachuk E.A., Seminsky I.Zh. GENOME EDITING (LECTURE). Baikal Medical Journal. 2025;4(1):84-97. (In Russ.) https://doi.org/10.57256/2949-0715-2025-4-1-84-97
Views:
286
